Hypertension, Pulmonary, Ventricular Dysfunction, Left
Conditions
Keywords
pulmonary hypertension, cardiac surgery, Glenn surgery, fontan surgery, left ventricular assist device, LVAD
Brief summary
Sixteen Japanese subjects (6 adults/10 children) with peri- and post-operative pulmonary hypertension associated with cardiac surgery will be evaluated at approx. 6 sites for safety and efficacy of IK-3001.
Detailed description
This is a multi-center, open-label, clinical study of the safety and efficacy of IK-3001 in 16 subjects with peri- and post-operative pulmonary hypertension associated with cardiac surgery. Two primary sub-sets of this patient population will be evaluated in this study: 1. Adults with severe congestive heart failure having LVAD implant 2. Children requiring surgery for congenital heart disease with corresponding PH or having Glenn surgery or Fontan surgery for single-ventricle physiology. Children with severe pulmonary hypertension due to congenital heart disease who require inhaled nitric oxide (iNO) pre-operatively may also be enrolled.
Interventions
DRUGIK-3001
Sponsors
Mallinckrodt
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects must meet one of the following criteria: 1. Adults, aged 15 to 80 years, with severe congestive heart failure (CHF) and scheduled for left ventricular assist device (LVAD) placement; or 2. Children, aged \< 15 years, scheduled for surgery for congenital heart disease which may associate pulmonary hypertension (PH)(including children with severe PH due to congenital heart failure and with severe hypoxemia secondary to high pulmonary vascular resistance or either a history or a possibility of developing PH crisis, who are deemed by an investigator or subinvestigator to require IK-3001 pre-operatively); or 3. Children, aged \< 15 years, with congenital heart disease and scheduled for Glenn surgery; or 4. Children, aged \< 15 years, with congenital heart disease and scheduled for Fontan surgery. 2. For women of childbearing potential, a negative result for a pregnancy test documented prior to enrollment. 3. Subjects must give written informed consent. If the subject is a minor the subject's legally acceptable representative (parent or legal guardian) must give written informed consent.
Exclusion criteria
1. Lung hypoplasia or other pre-existing severe lung disease; 2. Planned bi-ventricular support; 3. Participation in another clinical trial of an investigational agent within 28 days from the day of informed consent for this study including subjects who are deemed to carry a residual effect of an investigational product lasting more than 28 days from a previous investigational study; 4. Subjects with PH secondary to organic obstructive lesions in pulmonary arteries; 5. Subjects not under mechanical ventilation; 6. Investigator or subinvestigator decision that the subject is unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in mean pulmonary artery pressure (mPAP) in Adult subjects (with LVAD) | Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy |
| Change in partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio in Adult subjects (with LVAD) | Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy |
| Change in central venous pressure (CVP) in Children (with congenital heart disease) | Predose baseline to 24 hours (or final observation, if < 24 hours)(measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy |
| Change in partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio in Children (with congenital heart disease) | Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy |
Countries
Japan
Outcome results
None listed